Renalytix Plc (RENX) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the RENOLIX conference call to review second quarter and first half fiscal year 2023 financial results. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DiNardo of Capcom Partners for a few introductory comments. Thank you, Michelle. Good morning and welcome to the RenoLytics conference call to review second quarter and first half fiscal year 2023 financial results. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. Thank you all for participating in today's call. Joining me today for bringing the lights to bright formal remarks are James McCullough, Chief Executive Officer, Tom McClain, President, and James Sterling, Chief Financial Officer. In addition, Fergus Fleming, Chief Technology Officer, will be on hand to join us for the question and answer session. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Examples of these statements include, without limitation, the potential benefits, including economic savings, of kidney intellects, the potential for kidney intellects to receive regulatory clearance from the FDA, the commercial prospects of kidney intellects, including whe...